Suchen Sie nach Informationen zu Servier-Unternehmenszentrale? Folgen Sie den Links unten, um alle Informationen zu finden, die Sie benötigen, und mehr.
the Group’s medicines. are distributed. > 20 %. of brand-name revenue. invested in R&D every year. € 4.7 billion. euros in revenue in 2020/2021 comprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines. 4 …
https://servier.com/en/group/
We are a global pharmaceutical Group governed by a non-profit Foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to transmit to future generations a world that can ensure access ...
https://servier-me.com/en/
in revenue in 2020/2021 comprising €3.3. billion for brand-name medicines and €1.4 billion for generic medicines.
https://www.servier.us/servier-global-RD-center-and-office
Servier Pharmaceuticals LLC is a commercial-stage company with a passion for innovation and improving the lives of patients, their families and caregivers. As a privately held company, Servier has the unique freedom to devote all of its time and energy towards patients who require our treatments, care and innovation in areas of unmet medical need.
https://servier.com/en/areas-of-expertise/research-and-development/development-pipeline/
OUR DEVELOPMENT PIPELINE. In order to optimize the success of its Research and Development projects, Servier has decided to focus its efforts in four therapeutic areas with considerable needs—oncology, immuno-inflammation, neuroscience and cardiometabolism. ONCOLOGY. CARDIOMETABOLISM.
https://www.servier.us/fda-approval-tibsovo-aml
Servier Pharmaceuticals LLC is a commercial-stage company with a passion for innovation and improving the lives of patients, their families and caregivers. As a privately held company, Servier has the unique freedom to devote all of its time and energy towards patients who require our treatments, care and innovation in areas of unmet medical need.
https://www.servier.us/servier-asco-eha-2022
BOSTON, June 1, 2022 – Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that data will be presented from multiple studies across its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7 and the European Hematology ...
https://www.servier.us/servier-statement
Servier Statement on U.S. Supreme Court Overturning Roe v. Wade. By. Servier. June 30, 2022. One of our core values has and will always be to care. As leaders in healthcare, we are deeply committed to the health and well-being of the patients we serve and also that of our team members and their families. As such, it is our duty to guarantee ...
https://servier.com/en/news/servier-completes-acquisition-of-agios-pharmaceuticals-oncology-business/
01/04/2021. On April 1st , 2021, Servier announced the successful acquisition of Agios Pharmaceuticals’ commercial, clinical, and research-stage oncology portfolio. This acquisition immediately strengthens Servier’s commercial presence in the U.S. malignant hematology market and provides the potential for long-term growth into the solid ...
https://servier.com/en/communique/servier-certified-top-employer-europe-2022/
20/01/2022. Servier certified Top Employer Europe 2022. Paris, France, January 20, 2022 – For the second year in a row, the Servier Group has obtained Top Employer certification in six countries where it operates: Belgium, Spain, France, Greece, Italy and Portugal. Thanks to these regional certifications, Servier has obtained the Top Employer ...
Wir hoffen, dass Sie über die obigen Links alle notwendigen Informationen zu Servier-Unternehmenszentrale gefunden haben.
